Acromegaly
Conditions
Keywords
acromegaly, irradiation, remission, pituitary function
Brief summary
Hypothesis: Fractionated stereotactic radiotherapy is a safe therapy for treatment of patients with acromegaly in terms of both tumour control and biochemical remission
Detailed description
An audit was done on 34 patients with acromegaly (consecutive cohorte) treated with fractionated stereotactic radiotherapy in Rigshospitalet/National University Hospital, Copenhagen, Denmark. All patients had MR control regularly to monitor tunour control, and biochemical control assessed by growth hormone measurements during an oral glucose tolerance test. Furthermore all other pituitary axes were tested for sufficiency and concomitant medication likewise registered. The 7 year interim analysis demonstrated an acceptable tumour control and biochemical remission profile, and most patient had subsequent withdrawal of somatostatin analogue- and growth hormone receptor antagonis therapy. The observational study will continue with a new update in approx 2 years
Interventions
Audit of outcome
Sponsors
Rigshospitalet, Denmark
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
adults active acromegaly pituitary tumour on MRI biochemical activity -
Exclusion criteria
pregnancy no visible tumour on MRI \-
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumour control by pituitary MRI | 7 years |
Secondary
| Measure | Time frame |
|---|---|
| biochemical remission | 10 years |
| Affection of other pituitary axes | 10 years |
| withdrawal of somatostatin analogue and growth hormone receptor antagomist | 10 years |
Countries
Denmark
Outcome results
None listed